US2003077658A1PendingUtilityA1

Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses

46
Assignee: MAGNESIUM DIAGNOSTICS INCPriority: Mar 10, 1999Filed: Jan 24, 2002Published: Apr 24, 2003
Est. expiryMar 10, 2019(expired)· nominal 20-yr term from priority
Inventors:Ibert Clifton Wells
G01N 2800/321G01N 2800/042G01N 33/6893
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to methods for detecting the deficiency of magnesium tightly bound to cellular membranes, i.e., magnesium binding defect, which deficiency is associated with certain abnormal physiological states, e.g., salt-sensitive essential hypertension or Type 2 diabetes mellitus.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A monoclonal or polyclonal antibody having high affinity for a peptide selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH 2 , where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:2).  
     
     
         2 . The antibody of  claim 1 , wherein said antibody is a monoclonal antibody.  
     
     
         3 . The antibody of  claim 1 , wherein said antibody has high affinity for the peptide Phe-Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:1).  
     
     
         4 . The antibody of  claim 2 , wherein said antibody has high affinity for the peptide Phe-Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:1).  
     
     
         5 . The antibody of  claim 1 , wherein said antibody has high affinity for the peptide Phe-Xaa-Gly-Leu-Met-NH 2 , where Xaa is variant Phe or Val (SEQ ID NO:4).  
     
     
         6 . The antibody of  claim 2 , wherein said antibody has high affinity for the peptide Phe-Xaa-Gly-Leu-Met-NH 2 , where Xaa is variant Phe or Val (SEQ ID NO:4).  
     
     
         7 . The antibody of  claim 1 , wherein said antibody has high affinity for the peptide Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:2).  
     
     
         8 . The antibody of  claim 2 , wherein said antibody has high affinity for the peptide Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:2).  
     
     
         9 . The antibody of  claim 1 , wherein said antibody is cross-reactive with each of peptides Phe-Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH 2 , where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:2).  
     
     
         10 . The antibody of  claim 2 , wherein said antibody is cross-reactive with each of peptides Phe-Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH 2 , where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:2).  
     
     
         11 . A method for detecting magnesium binding defect comprising: 
 a) measuring in blood serum the level of peptide having an amino acid sequence selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH 2 , where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:2); and    b) comparing said level to a standard, 
 wherein a reduced level of said peptide is indicative of said magnesium binding defect.  
   
     
     
         12 . The method of  claim 11 , wherein said level of peptide is measured by using an antibody to peptide having an amino acid sequence selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH 2 , where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:2).  
     
     
         13 . The method of  claim 12 , wherein the antibody is monoclonal.  
     
     
         14 . The method of  claim 13 , wherein the monoclonal antibody cross reacts with each of said peptides.  
     
     
         15 . The method of  claim 12 , wherein the antibody is employed in an immunoenzyme assay.  
     
     
         16 . The method of  claim 15 , wherein the immunoenzyme assay is enzyme-linked immunosorbent assay to quantitate the concentration of said peptide in blood serum.  
     
     
         17 . The method of  claim 12 , wherein the antibody is polyclonal.  
     
     
         18 . A method for correcting magnesium binding defect of an individual comprising administering to said individual peptide having an amino acid sequence selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH 2 , where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH 2  (SEQ ID NO:2).  
     
     
         19 . The method of  claim 18 , wherein said peptide is administered in an amount sufficient to correct magnesium binding defect.  
     
     
         20 . The method of  claim 19 , wherein the peptide is administered intravenously.

Join the waitlist — get patent alerts

Track US2003077658A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.